Coexistence of YWHAZ amplification predicts better prognosis in muscle-invasive bladder cancer with CDKN2A or TP53 loss
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1575 views | HTML 1932 views | ?
Shenghua Liu1,2, Yishuo Wu1,2, Tian Yang1,2, Chenchen Feng1,2, Haowen Jiang1,2
1Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai 200040, China
2Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, China
Chenchen Feng, email: drfengche[email protected]
Haowen Jiang, email: [email protected]
Keywords: YWHAZ, copy number alteration, amplification, prognosis, bladder cancer
Received: February 28, 2016 Accepted: April 16, 2016 Published: May 04, 2016
The amplification of YWHAZ was commonly seen in bladder cancer. We explore the biological significance of YWHAZ amplification on bladder cancer, and the correlation with important other molecular events. The Cancer Genome Atlas (TCGA) database was exploited to study the impact of YWHAZ amplification on either CDKN2A or TP53 mutations. The Database for Annotation, Visualization and Integrated Discovery (DAVID) was also exploited to clustering of enriched genes in the cBioPortal Enrichment tests. There were 127 cases with available mutation and CNV data in the corresponding TCGA bladder cancer dataset, 20% of them had YWHAZ alteration. Patients with both YWHAZ amplification and CDKN2A loss demonstrated significantly better overall survival (OS) compared with CDKN2A loss alone. Patients with both YWHAZ amplification and TP53 mutation demonstrated significantly better overall survival (OS) and disease-free survival (DFS) compared with TP53 mutation alone. The amplification of YWHAZ, along with alteration of CDKN2A or TP53, predict better survival in bladder cancers that only had CDKN2A or TP53 alteration. The protective role of YWHAZ in bladder cancer deserve insightful further studies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.